688319 Stock Overview
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines.
Chengdu Olymvax Biopharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥13.91|
|52 Week High||CN¥40.59|
|52 Week Low||CN¥13.32|
|1 Month Change||-14.72%|
|3 Month Change||-23.99%|
|1 Year Change||-57.44%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-65.14%|
Recent News & Updates
|688319||CN Biotechs||CN Market|
Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -33.6% over the past year.
Return vs Market: 688319 underperformed the CN Market which returned -19.2% over the past year.
|688319 Average Weekly Movement||4.7%|
|Biotechs Industry Average Movement||5.0%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.2%|
|10% least volatile stocks in CN Market||3.8%|
Stable Share Price: 688319 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 688319's weekly volatility (5%) has been stable over the past year.
About the Company
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.
Chengdu Olymvax Biopharmaceuticals Fundamentals Summary
|688319 fundamental statistics|
Is 688319 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|688319 income statement (TTM)|
|Cost of Revenue||CN¥37.92m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.24|
|Net Profit Margin||17.55%|
How did 688319 perform over the long term?See historical performance and comparison
Is 688319 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688319?
Other financial metrics that can be useful for relative valuation.
|What is 688319's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 688319's PE Ratio compare to its peers?
|688319 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
603387 Getein Biotech
002880 Shenzhen Weiguang Biological Products
300485 Beijing Science Sun Pharmaceutical
688767 Hangzhou Biotest BiotechLtd
688319 Chengdu Olymvax Biopharmaceuticals
Price-To-Earnings vs Peers: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the peer average (13.6x).
Price to Earnings Ratio vs Industry
How does 688319's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings vs Industry: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the CN Biotechs industry average (30x)
Price to Earnings Ratio vs Fair Ratio
What is 688319's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||58.3x|
|Fair PE Ratio||36.3x|
Price-To-Earnings vs Fair Ratio: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).
Share Price vs Fair Value
What is the Fair Price of 688319 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Chengdu Olymvax Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688319's forecast earnings growth (41.3% per year) is above the savings rate (3.2%).
Earnings vs Market: 688319's earnings (41.3% per year) are forecast to grow faster than the CN market (25.8% per year).
High Growth Earnings: 688319's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688319's revenue (29.3% per year) is forecast to grow faster than the CN market (18.1% per year).
High Growth Revenue: 688319's revenue (29.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (18.1%).
Discover growth companies
How has Chengdu Olymvax Biopharmaceuticals performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 688319 has a high level of non-cash earnings.
Growing Profit Margin: 688319's current net profit margins (17.5%) are higher than last year (17.3%).
Past Earnings Growth Analysis
Earnings Trend: 688319 has become profitable over the past 5 years, growing earnings by 52% per year.
Accelerating Growth: 688319's earnings growth over the past year (47.7%) is below its 5-year average (52% per year).
Earnings vs Industry: 688319 earnings growth over the past year (47.7%) exceeded the Biotechs industry 9.7%.
Return on Equity
High ROE: 688319's Return on Equity (11%) is considered low.
Discover strong past performing companies
How is Chengdu Olymvax Biopharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its short term liabilities (CN¥386.7M).
Long Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its long term liabilities (CN¥38.9M).
Debt to Equity History and Analysis
Debt Level: 688319 has more cash than its total debt.
Reducing Debt: 688319's debt to equity ratio has increased from 2.2% to 11.4% over the past 5 years.
Debt Coverage: 688319's debt is not well covered by operating cash flow (12.6%).
Interest Coverage: 688319 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Chengdu Olymvax Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Chengdu Olymvax Biopharmaceuticals Dividend Yield vs Market|
|Company (Chengdu Olymvax Biopharmaceuticals)||n/a|
|Market Bottom 25% (CN)||0.5%|
|Market Top 25% (CN)||2.2%|
|Industry Average (Biotechs)||0.9%|
|Analyst forecast in 3 Years (Chengdu Olymvax Biopharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate 688319's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 688319's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 688319's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 688319's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 688319 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shaowen Fan (69 yo)
Mr. Shaowen Fan is Genenral Manager & Chairman of the Board of Chengdu Olymvax Biopharmaceuticals Inc. since 2019.
Experienced Management: 688319's management team is seasoned and experienced (12.8 years average tenure).
Experienced Board: 688319's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Chengdu Olymvax Biopharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Chengdu Olymvax Biopharmaceuticals Inc.
- Ticker: 688319
- Exchange: SHSE
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥5.637b
- Shares outstanding: 405.27m
- Website: https://www.olymvax.com
Number of Employees
- Chengdu Olymvax Biopharmaceuticals Inc.
- No. 99 Tianxin Road
- Hi-Tech Zone (West)
- Sichuan Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|688319||SHSE (Shanghai Stock Exchange)||Yes||Domestic Shares||CN||CNY||Jun 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/05 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.